Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition charges clouding the quarter, here is where the stock heads next. The 24/7 ...

Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock ...

Okay, I thought Merck got, you know what, Merck reported a really good quarter, and it just happened on a day when people ...

Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...

Janux Therapeutics, Inc. upgraded to Strong Buy: below cash value, strong runway, TRACTr progress, Merck/BMY milestones.

Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key moving averages and ...

Futures are trading higher on Wednesday as news of an impending end to the Iran war is sending oil prices dramatically lower.

It's time to start thinking at least a little bit defensively by exchanging long-term potential gains for certain near-term ...

Is PGEN a good stock to buy? We came across a bullish thesis on Precigen, Inc. on Valueinvestorsclub.com by coalone. In this ...

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

Shares of Zoetis Inc. cratered 21.50% to $87.31 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.38% to 7,337.11 and Dow Jones ...

Stroke drug developer Argenica Therapeutics plans a second trial to test its novel candidate, in a sector that has few ...